Genomics has significantly advanced personalized preventative healthcare with the launch of its Health Insights test across Great Britain, marking a pivotal moment as the first UKCA marked and MHRA registered product to combine genetic and clinical data for disease prediction and prevention. This innovative tool, unveiled at HLTH Europe 2025, specifically targets major preventable conditions including cardiovascular disease, type 2 diabetes, prostate cancer, and breast cancer. At its core, Health Insights leverages cutting-edge Polygenic Risk Scores (PRS), which are derived from a single, lifelong genetic test. Unlike traditional methods that might focus on rare, high-impact mutations or only family history, PRS utilizes sophisticated algorithms to analyze millions of common genetic variants across an individual's DNA. This comprehensive approach provides a summary of a person's overall genetic susceptibility to specific diseases, revealing risks that are often uncorrelated with family history or conventional clinical risk factors. By integrating these genetic insights with other relevant health data, Health Insights empowers healthcare professionals to offer truly personalized recommendations, enabling them to guide the right patients into appropriate prevention and screening programs at the optimal time, years before symptoms might develop. This proactive approach aims to fundamentally change the patient experience, transforming individuals from passive recipients of care into "co-pilots" actively engaged in managing their long-term health. The UK launch follows a successful trial of a cardiovascular risk tool in the NHS in 2021, and with its Health Insights US product already established, Genomics is actively pursuing global expansion, in addition to its ongoing collaborations with major life sciences organizations for drug discovery, underpinned by its globally recognized genotype-phenotype research database.